Cargando…
Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts
Glioblastoma is a highly aggressive disease with poor patient outcomes despite current treatment options, which consist of surgery, radiation, and chemotherapy. However, these strategies present challenges such as resistance development, damage to healthy tissue, and complications due to the blood–b...
Autores principales: | Dhungel, Laxmi, Harris, Cayla, Romine, Lauren, Sarkaria, Jan, Raucher, Drazen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294868/ https://www.ncbi.nlm.nih.gov/pubmed/37370649 http://dx.doi.org/10.3390/bioengineering10060718 |
Ejemplares similares
-
Thermally Targeted Delivery of a c-Myc Inhibitory Polypeptide Inhibits Tumor Progression and Extends Survival in a Rat Glioma Model
por: Bidwell, Gene L., et al.
Publicado: (2013) -
Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma
por: Dragojevic, Sonja, et al.
Publicado: (2019) -
Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives
por: Raucher, Drazen, et al.
Publicado: (2018) -
Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma
por: Yamaki, Tomohiro, et al.
Publicado: (2013) -
TRANSLATIONAL RESEARCH-03 MULTIPLE MECHANISMS MODULATE TEMOZOLOMIDE RESISTANCE AND ARE POTENTIAL TARGETS FOR GLIOBLASTOMA THERAPY.
por: Kitange, Gaspar, et al.
Publicado: (2023)